Description
Insulin-Like Growth Factor Analogue · Research Grade · Performance → · Metabolic →
IGF-1 LR3 Research Spray
Captide Labs IGF-1 LR3 Spray delivers research-grade Long Arg3 Insulin-like Growth Factor-1 in a pre-formulated, ready-to-use liquid spray format. Each 30ml bottle contains 2mg of IGF-1 LR3 at greater than 98% purity, independently verified by HPLC-MS analysis and documented with a full Certificate of Analysis. Each actuation delivers 200–500mcg depending on application protocol.
IGF-1 LR3 (CAS 946870-92-4) is a synthetic 83-amino acid analogue of human insulin-like growth factor-1. It was engineered with two structural modifications that dramatically alter its pharmacokinetic profile: a glutamic acid to arginine substitution at position 3 (the “R3”), and a 13-amino acid extension at the N-terminus (the “Long”). Together, these changes reduce binding to IGF-binding proteins (IGFBPs) and extend its half-life from the minutes typical of native IGF-1 to approximately 20–30 hours — making it approximately three times more potent and substantially longer-acting in experimental models.
|
Compound
IGF-1 LR3 (Long Arg3 IGF-1)
|
CAS Number
946870-92-4
|
|
Amino Acids
83 (vs. 70 in native IGF-1)
|
Purity
>98% (HPLC-MS Verified)
|
|
Molecular Formula
C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
|
Molecular Weight
9,117.5 g/mol
|
|
Format
Liquid Spray
|
Concentration
0.067mg/ml (2mg / 30ml)
|
|
Spray Delivery
200–500mcg per actuation
|
Bottle Volume
30ml
|
|
Total Peptide
2mg
|
Testing Standard
ISO 17025 Accredited Lab
|
|
Storage
Refrigerate at 2–8°C. Do not freeze once in liquid form. Keep away from light. Use within 28–30 days of opening.
|
|
What is IGF-1 LR3?
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is a synthetic 83-amino acid recombinant protein analogue of human IGF-1. It was designed for research applications requiring prolonged IGF-1 receptor activation without the rapid clearance that limits native IGF-1 utility in experimental systems. Two structural modifications define its pharmacological profile: first, a glutamic acid to arginine substitution at amino acid position 3, which dramatically reduces binding affinity to IGF-binding proteins (IGFBPs); and second, a 13-amino acid N-terminal extension (MFPAMPLSSLF VN), which further reduces IGFBP binding and contributes to enhanced receptor engagement. Together these changes extend half-life to approximately 20–30 hours versus the 12–15 minute half-life of native IGF-1, and increase potency approximately three-fold.
IGF-1 LR3 was originally developed for use in cell culture media to improve the growth performance of mammalian cells in bioreactor systems — it is widely used as a serum-free media supplement in pharmaceutical and biologics manufacturing. In the research peptide space, it has been extensively studied for its direct activation of the IGF-1 receptor and downstream PI3K/Akt and MAPK/ERK signaling cascades in models of cellular growth, tissue repair, and metabolic regulation.
Areas of active investigation
Frequently Asked Questions
For research use only. Not for human consumption, veterinary use, or food/agricultural applications. Not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. All purchases are made with the understanding that this compound is strictly for in-vitro research and laboratory use.





Reviews
There are no reviews yet.